IMAGE BASED SMALL ANIMAL PHENOTYPING

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 背景资料： 髓母细胞瘤是最常见的儿童脑肿瘤， 因为肿瘤本质上是围产期神经干细胞在脑内的过度生长， 小脑的外部颗粒层。髓母细胞瘤发生在小脑早期 在儿童时期，与出生后发生的小脑发育一致 通过体外颗粒层（EGL）细胞的增殖和分化， 小脑。这个项目致力于髓母细胞瘤的生化基础 通过凯勒实验室开发的基因工程小鼠模型（GEM）。 基本原理： 在他们最近的出版物中，凯勒实验室发现了一种新的机制， 髓母细胞瘤的疾病进展，以及临床可用的药物， 并逆转肿瘤生长。他们已经证明，硼替佐米（velcade，PS-341），一种26 S 蛋白酶体抑制剂，对髓母细胞瘤具有显着的抗肿瘤活性， 伴随Ptc 1蛋白的恢复（来自第二个非突变等位基因）， 下调hedgehog信号通路。这项工作是一项正在进行的 在小鼠中反向遗传学的策略作为一种方法来确定的贡献， 从单个基因到复杂的生物过程，如发育模式。 问题： 该DBP对CIBC提出了几个重要挑战：（1）建立管道， 分割小鼠的小脑;（2）解决更普遍的问题， 具有相对高曲率特征的复杂形状， 分析;（3）执行大量的3D可视化。 设计与方法： 方案设计主要有三个目标：（1）宏观量化， 在21天的肿瘤前（肿瘤前）阶段的形态学变化， 髓母细胞瘤小鼠;（2）表征肿瘤形状和侵袭性 在生命的前六周内发展的已建立的髓母细胞瘤;和（3） 开发一种基于形状的生物标志物，以量化 硼替佐米治疗髓母细胞瘤

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Background: Medulloblastoma is the most common childhood brain tumor and is of scientific interest because tumors are essentially overgrowths of perinatal neuronal stem cells in the external granular layer of the cerebellum. Medulloblastomas arise in the cerebellum early in childhood, coincident with the development of the cerebellum, which occurs after birth by the proliferation and differentiation of the cells in the external granular layer (EGL) of the cerebellum. This project addresses the biochemical underpinnings of medulloblastoma through a genetically engineered mouse model (GEM), developed by the Keller laboratory. Rationale: In their recent publication, the Keller laboratory has uncovered a new mechanism of disease progression for medulloblastoma, as well as a clinically-available drug that halts and reverses tumor growth. They have shown that bortezomib (velcade, PS-341), a 26S proteasome inhibitor, had significant anti-tumor activity in medulloblastoma, which was accompanied by restoration of Ptc1 protein (from the second, non-mutated allele) and downregulation of the hedgehog signaling pathway. This work represents an ongoing strategy of reverse genetics in the mouse as a way of determining the contribution of a single gene to a complex biological process, such as developmental patterning. Questions: This DBP poses several important challenges for the CIBC: (1) Establishing a pipeline for segmenting the cerebellum of the mice; (2) Addressing the more general problem of complex shape with relatively high-curvature features that present variations important to the analysis; and (3) Performing a significant amount of 3D visualization. Design & Methods: The project design consists of three essentials aims: (1) Quantify macroscopic, morphological changes in the 21-day preneoplastic (pretumor) phase for the medulloblastomaprone mice; (2) Characterize tumor shape and invasiveness of established medulloblastomas as they develop in the first six weeks of life; and (3) Develop a shape-based biomarker to quantify the therapeutic efficacy and mechanisms of bortezomib on medulloblastomas.